GSK-3β directly phosphorylates and activates MARK2/PAR-1

Shinichi Kosuga, Etsu Tashiro, Toshifumi Kajioka, Mayumi Ueki, Yoshifumi Shimizu, Masaya Imoto

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

In Alzheimer disease (AD), the microtubule-associated protein tau is found hyperphosphorylated in paired helical filaments. Among many phosphorylated sites in tau, Ser-262 is the major site for abnormal phosphorylation of tau in AD brain. The kinase known to phosphorylate this particular site is MARK2, whose activation mechanism is yet to be studied. Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3β (GSK-3β), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3β in MARK2 activation. In vitro kinase reaction revealed that recombinant GSK-3β indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau. Our further findings led us to conclude that GSK-3β phosphorylates MARK2 on Ser-212, one of the two reported phosphorylation sites (Thr-208 and Ser-212) found in the activation loop of MARK2. Down-regulation of either GSK-3β or MARK2 by small interfering RNAs suppressed the level of phosphorylation on Ser-262. These results, respectively, indicated that GSK-3β is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3β-MARK2 pathway. These findings are of interest in the context of the pathogenesis of AD.

Original languageEnglish
Pages (from-to)42715-42722
Number of pages8
JournalJournal of Biological Chemistry
Volume280
Issue number52
DOIs
Publication statusPublished - 2005 Dec 30

Fingerprint

Glycogen Synthase Kinase 3
Phosphorylation
Chemical activation
Alzheimer Disease
Phosphotransferases
Microtubule-Associated Proteins
Small Interfering RNA
Brain
Down-Regulation
Cells

ASJC Scopus subject areas

  • Biochemistry

Cite this

GSK-3β directly phosphorylates and activates MARK2/PAR-1. / Kosuga, Shinichi; Tashiro, Etsu; Kajioka, Toshifumi; Ueki, Mayumi; Shimizu, Yoshifumi; Imoto, Masaya.

In: Journal of Biological Chemistry, Vol. 280, No. 52, 30.12.2005, p. 42715-42722.

Research output: Contribution to journalArticle

Kosuga, Shinichi ; Tashiro, Etsu ; Kajioka, Toshifumi ; Ueki, Mayumi ; Shimizu, Yoshifumi ; Imoto, Masaya. / GSK-3β directly phosphorylates and activates MARK2/PAR-1. In: Journal of Biological Chemistry. 2005 ; Vol. 280, No. 52. pp. 42715-42722.
@article{03926efd3b6144148ec25aa2e9b23471,
title = "GSK-3β directly phosphorylates and activates MARK2/PAR-1",
abstract = "In Alzheimer disease (AD), the microtubule-associated protein tau is found hyperphosphorylated in paired helical filaments. Among many phosphorylated sites in tau, Ser-262 is the major site for abnormal phosphorylation of tau in AD brain. The kinase known to phosphorylate this particular site is MARK2, whose activation mechanism is yet to be studied. Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3β (GSK-3β), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3β in MARK2 activation. In vitro kinase reaction revealed that recombinant GSK-3β indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau. Our further findings led us to conclude that GSK-3β phosphorylates MARK2 on Ser-212, one of the two reported phosphorylation sites (Thr-208 and Ser-212) found in the activation loop of MARK2. Down-regulation of either GSK-3β or MARK2 by small interfering RNAs suppressed the level of phosphorylation on Ser-262. These results, respectively, indicated that GSK-3β is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3β-MARK2 pathway. These findings are of interest in the context of the pathogenesis of AD.",
author = "Shinichi Kosuga and Etsu Tashiro and Toshifumi Kajioka and Mayumi Ueki and Yoshifumi Shimizu and Masaya Imoto",
year = "2005",
month = "12",
day = "30",
doi = "10.1074/jbc.M507941200",
language = "English",
volume = "280",
pages = "42715--42722",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "52",

}

TY - JOUR

T1 - GSK-3β directly phosphorylates and activates MARK2/PAR-1

AU - Kosuga, Shinichi

AU - Tashiro, Etsu

AU - Kajioka, Toshifumi

AU - Ueki, Mayumi

AU - Shimizu, Yoshifumi

AU - Imoto, Masaya

PY - 2005/12/30

Y1 - 2005/12/30

N2 - In Alzheimer disease (AD), the microtubule-associated protein tau is found hyperphosphorylated in paired helical filaments. Among many phosphorylated sites in tau, Ser-262 is the major site for abnormal phosphorylation of tau in AD brain. The kinase known to phosphorylate this particular site is MARK2, whose activation mechanism is yet to be studied. Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3β (GSK-3β), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3β in MARK2 activation. In vitro kinase reaction revealed that recombinant GSK-3β indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau. Our further findings led us to conclude that GSK-3β phosphorylates MARK2 on Ser-212, one of the two reported phosphorylation sites (Thr-208 and Ser-212) found in the activation loop of MARK2. Down-regulation of either GSK-3β or MARK2 by small interfering RNAs suppressed the level of phosphorylation on Ser-262. These results, respectively, indicated that GSK-3β is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3β-MARK2 pathway. These findings are of interest in the context of the pathogenesis of AD.

AB - In Alzheimer disease (AD), the microtubule-associated protein tau is found hyperphosphorylated in paired helical filaments. Among many phosphorylated sites in tau, Ser-262 is the major site for abnormal phosphorylation of tau in AD brain. The kinase known to phosphorylate this particular site is MARK2, whose activation mechanism is yet to be studied. Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3β (GSK-3β), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3β in MARK2 activation. In vitro kinase reaction revealed that recombinant GSK-3β indeed phosphorylates MARK2, whereas it failed to phosphorylate Ser-262 of tau. Our further findings led us to conclude that GSK-3β phosphorylates MARK2 on Ser-212, one of the two reported phosphorylation sites (Thr-208 and Ser-212) found in the activation loop of MARK2. Down-regulation of either GSK-3β or MARK2 by small interfering RNAs suppressed the level of phosphorylation on Ser-262. These results, respectively, indicated that GSK-3β is responsible for phosphorylating Ser-262 of tau through phosphorylation and activation of MARK2 and that the phosphorylation of tau at this particular site is predominantly mediated by a GSK-3β-MARK2 pathway. These findings are of interest in the context of the pathogenesis of AD.

UR - http://www.scopus.com/inward/record.url?scp=30044448126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30044448126&partnerID=8YFLogxK

U2 - 10.1074/jbc.M507941200

DO - 10.1074/jbc.M507941200

M3 - Article

C2 - 16257959

AN - SCOPUS:30044448126

VL - 280

SP - 42715

EP - 42722

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 52

ER -